Olmesartan dehydro is an impurity and process-related substance identified during the synthesis of olmesartan medoxomil, a potent angiotensin II receptor blocker (ARB) primarily used to treat hypertension… Read more








![Chemical structure of Ethyl 4-(2-Hydroxypropan-2-yl)-2-propyl-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylate](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F144690-33-5-Ethyl-4-2-Hydroxypropan-2-yl-2-propyl-1-2-1-trityl-1H-tetrazol-5-yl-11-biphenyl-4-ylmethyl-1H-imidazole-5-carboxylate.png&w=3840&q=75)













Olmesartan dehydro is an impurity and process-related substance identified during the synthesis of olmesartan medoxomil, a potent angiotensin II receptor blocker (ARB) primarily used to treat hypertension by managing blood pressure and reducing cardiovascular risk. Because the presence of impurities must be strictly controlled to meet regulatory safety requirements, pharmaceutical laboratories require high-quality reference standards for rigorous quality control and method validation. This category provides essential materials for comprehensive impurity profiling, allowing analysts to accurately detect and quantify degradation products and synthetic by-products. By offering access to these standards, as well as stable isotope labelled compounds, this collection supports the development of robust analytical methods necessary for maintaining the consistency and efficacy of pharmaceutical formulations containing this antihypertensive medication.